lifestyle.pspl.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
May 8, 2026
Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026
May 8, 2026
Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 8, 2026
Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
May 3, 2026
Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights
April 29, 2026
Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
February 25, 2026
Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant
February 24, 2026
Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors
February 19, 2026
Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHL
January 24, 2026